Advanced Solid Malignancies Clinical Trial
Official title:
A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W)
Verified date | April 2013 |
Source | Hanmi Pharmaceutical Company Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
The main objective of this study is to determine the maximum tolerated dose (MTD) of
OratecanTM. Eligible subjects of this study are patients with histologically or
cytologically confirmed malignant solid tumor refractory to standard therapy.
The irinotecan hydrochloric acid (HCl) tablet is escalated and administered per body surface
area (BSA). The dose of HM30181A 60 mg is fixed.
The Route of administration of irinitecan and HM30181A is oral. Each cycle consists of 21
days. Drugs are administered daily for 10 consecutive days (D1, 2, 3, 4, 5, 8, 9, 10, 11 and
12) followed by a washout of 9 days.
Status | Completed |
Enrollment | 14 |
Est. completion date | September 2012 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed advanced solid tumors - Patients who have experienced progressive disease despite of conventional anticancer therapy. Patients who cannot expect effective treatment or prolonged survival with conventional anticancer therapy - Previous chemotherapy (excluding irinotecan), radiotherapy and surgical operation are allowed if they are discontinued for at least 4 weeks prior to D0 and all adverse events are resolved (6 weeks for nitrosoureas and mitomycin) - Aged =18 - Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2 - A life expectancy greater than 12 weeks - Adequate bone marrow (platelet=100 x 109/L, hemoglobin=10.0g/dl and ANC= 1.5 x 109/L, renal (Creatinine=1.5mg/dl) and liver function (AST/ALT/ALP = 3 x upper limit of normal and total bilirubin=2mg/dl) and no abnormal heart and lung function However, AST/ALT/ALP = 5 x upper limit of normal for patients with liver metastases and ALP level = 5 x upper limit of normal for patients with bone metastases are allowed. - Patients with no need of radiotherapy (except for true oncologic emergency occurring after entry on study [e.g. acute spinal cord compression], other anticancer drugs and immunotherapy during the trial - Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures Exclusion Criteria: - Patients with hematopoietic malignancies ( including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative disorders), ileus, CNS metastasis, and with active infections requiring parenteral or systemic antibacterial, antiviral, or antifungal therapy. Patients with infections may participate in this clinical trial after complete recovery or control of the infection - Patients with chronic malabsorption, or who have undergone total colectomy - Patients who have undergone hematopoietic stem cell transplantation (HSCT) or are candidates for planned HSCT - History of congestive heart failure, atrial arrhythmia or ventricular arrhythmia requiring medication; Patients who had treatment for myocardial infarction or any other acute coronary syndrome event within the past 6 months. - Subjects who, in the investigator's opinion, cannot be treated per protocol due to functional impairments due to any other severe co-morbid medical conditions - Pregnant or breast-feeding patients; Women of childbearing potential without adequate contraception (Men must use adequate contraception.) - Subjects who have no intention of following the requirements of the protocol or the follow-up management. Subjects who cannot be followed up regularly due to psychological, social, family, logistic, and geographical reasons. - Subjects who have been treated with PGP inhibitors (cyclosporine A and verapamil), which are contraindicated medications, will have a wash-out period of 2 weeks. - Subjects who were administered with other investigational products within 28 days before screening. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Hanmi Pharmaceutical Company Limited |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity evaluation (safety evaluation): Toxicity will be evaluated by medical history, vital signs, physical examination and laboratory tests performed during the screening period (D-28 to D0) and treatment period based on NCI-CTCAE (version 3.0). | Toxicity will be evaluated on Day 21 during Cycle 1 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02080078 -
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
|
Phase 1 | |
Completed |
NCT00981721 -
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00351325 -
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT00295243 -
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT02347228 -
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00979134 -
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
|
Phase 1 | |
Completed |
NCT00997945 -
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT05573724 -
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT03736473 -
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
|
Phase 1 | |
Completed |
NCT02260661 -
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
|
Phase 1 | |
Terminated |
NCT01219543 -
A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.
|
Phase 1 | |
Completed |
NCT01213160 -
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
|
Phase 1 | |
Completed |
NCT00572364 -
Open Label, Dose Escalation Phase I Study of AZD2281
|
Phase 1 | |
Completed |
NCT03363893 -
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04606381 -
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT05315167 -
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00879905 -
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00473616 -
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
|
Phase 1 | |
Recruiting |
NCT05159700 -
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01813474 -
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
|
Phase 1 |